FR2824475A1 - New topical composition containing silanol and alpha hydroxy acids to enhance its antiaging effects, is useful for preventing symptoms of skin aging - Google Patents
New topical composition containing silanol and alpha hydroxy acids to enhance its antiaging effects, is useful for preventing symptoms of skin aging Download PDFInfo
- Publication number
- FR2824475A1 FR2824475A1 FR0106271A FR0106271A FR2824475A1 FR 2824475 A1 FR2824475 A1 FR 2824475A1 FR 0106271 A FR0106271 A FR 0106271A FR 0106271 A FR0106271 A FR 0106271A FR 2824475 A1 FR2824475 A1 FR 2824475A1
- Authority
- FR
- France
- Prior art keywords
- composition according
- alpha
- composition
- silanol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 229940061720 alpha hydroxy acid Drugs 0.000 title claims abstract description 29
- 150000001280 alpha hydroxy acids Chemical class 0.000 title claims abstract description 25
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 208000024891 symptom Diseases 0.000 title claims abstract description 8
- 230000000699 topical effect Effects 0.000 title claims abstract description 7
- 230000003712 anti-aging effect Effects 0.000 title abstract description 3
- 230000009759 skin aging Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 230000032683 aging Effects 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- -1 dialkyl silane diols Chemical class 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 claims description 13
- 150000004819 silanols Chemical class 0.000 claims description 13
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 6
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical group C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims description 5
- 229940093767 glabridin Drugs 0.000 claims description 5
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims description 5
- 229960002591 hydroxyproline Drugs 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- 239000007854 depigmenting agent Substances 0.000 claims description 4
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 229960002510 mandelic acid Drugs 0.000 claims description 3
- 229940119168 tetrahexyldecyl ascorbate Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 claims 2
- YVTHGMMGMZKBHC-DKWTVANSSA-N (2S)-2-aminobutanedioic acid hydroxy(methyl)silane Chemical compound C[SiH2]O.N[C@@H](CC(=O)O)C(=O)O YVTHGMMGMZKBHC-DKWTVANSSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- MCFVCWVAZLRHPN-UHFFFAOYSA-N methade Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(CCC)C1=CC=CC=C1 MCFVCWVAZLRHPN-UHFFFAOYSA-N 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 26
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 230000016571 aggressive behavior Effects 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- 206010001488 Aggression Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940009098 aspartate Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NXTGWOGJZSSREB-HJXLNUONSA-N C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 Chemical compound C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 NXTGWOGJZSSREB-HJXLNUONSA-N 0.000 description 3
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940071097 ascorbyl phosphate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008269 hand cream Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- DKBVMOJIVATKCZ-NSHDSACASA-N (2s)-2-acetamido-3-[4-[dihydroxy(methyl)silyl]oxyphenyl]propanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O[Si](C)(O)O)C=C1 DKBVMOJIVATKCZ-NSHDSACASA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- XGPWIEKKIBAGSY-UHFFFAOYSA-N 2-oxopropane-1,1-disulfonic acid Chemical compound CC(=O)C(S(O)(=O)=O)S(O)(=O)=O XGPWIEKKIBAGSY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- QCYFYNAOZQVNBI-UHFFFAOYSA-M C[SiH2]O.C(C(O)C)(=O)[O-].[Na+] Chemical compound C[SiH2]O.C(C(O)C)(=O)[O-].[Na+] QCYFYNAOZQVNBI-UHFFFAOYSA-M 0.000 description 1
- HDETVIAMQNTONT-UHFFFAOYSA-N C[SiH2]O.[Na] Chemical compound C[SiH2]O.[Na] HDETVIAMQNTONT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- UGJZUKQBMQEKNC-UHFFFAOYSA-N [Na].C[SiH](O)C Chemical compound [Na].C[SiH](O)C UGJZUKQBMQEKNC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- NHJPVZLSLOHJDM-UHFFFAOYSA-N azane;butanedioic acid Chemical compound [NH4+].[NH4+].[O-]C(=O)CCC([O-])=O NHJPVZLSLOHJDM-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229940062933 dimethylsilanol hyaluronate Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
la peau.the skin.
j La présente invention concerne une nouvelle composition The present invention relates to a new composition
cosmétique, et plus particulièrement une composition compre- cosmetic, and more particularly a composition comprising
nant en combinaison un silanol et un alpha-hydroxy acide ou un sel ou ester d'alpha-hydroxy acide, utilisable par application s topique pour la protection de la peau et la prévention des affections de la peau, en particulier la prévention des nant in combination with a silanol and an alpha-hydroxy acid or a salt or ester of alpha-hydroxy acid, usable by topical application for the protection of the skin and the prevention of skin conditions, in particular the prevention of
symptômes liés à son vieillissement. symptoms related to aging.
La peau comprend trois parties, l'épiderme, le derme et l'hypoderme, dont chacune a des propriétés spécifiques faisant de cet ensemble un véritable organe réagissant et s'adaptant The skin consists of three parts, the epidermis, the dermis and the hypodermis, each of which has specific properties making this set a real reacting and adapting organ.
aux conditions de son environnement. to the conditions of its environment.
La main a pour particularité de présenter deux zones bien distinctes: la paume et le dessus de la main. Au niveau de la paume, la peau est épaisse et résistante. L'épiderme présente The particularity of the hand is that it presents two very distinct zones: the palm and the top of the hand. At the palm level, the skin is thick and resistant. The epidermis present
1S une hyperkératinisation, et l'hypoderme comporte des cous- 1S hyperkeratinization, and the hypodermis includes
sinets adipeux. La paume est donc relativement réaistante aux fatty sinets. The palm is therefore relatively resistant to
agressions extérieures.external aggressions.
Par contre, au niveau du dessus de la main, l'égiderme est fin et fragile. De plus, l'hypoderme y comporte peu de tissus adipeux. La peau de cette zone présente par contre une grande flexibilité, pour pouvoir être étirse lors des mouvements de la main et des doigts. Elle est souvent sollicitée et est exposée de manière quasi chronique aux agressions du soleil. Cette peau est donc soumise à un On the other hand, at the level of the top of the hand, the aegis is fine and fragile. In addition, the hypodermis contains little adipose tissue. The skin of this area, on the other hand, has great flexibility, so that it can be stretched during movements of the hand and fingers. It is often used and is exposed almost chronically to the aggressions of the sun. This skin is therefore subjected to a
vieillissement accéléré.accelerated aging.
Enfin, dans le cas des peaux à phototype clair, la sensibilité aux agressions du soleil est encore accrue. On observe alors également un vieillissement accéléré de ces Finally, in the case of skins with a clear phototype, the sensitivity to the aggressions of the sun is further increased. We also observe an accelerated aging of these
peaux claires.fair skin.
Par ailleurs, on sait que, pour être accep-ées par les utilisateurs, les compositions cosmétiques et!ou dermato logiques destinées au traitement et à la prévention des affections de la peau par application topique doiver.t être agréables à utiliser et présente' de bonnes propriétés physiques, notamment de consistance et d'onctuesité, tout en Furthermore, it is known that, in order to be accepted by users, the cosmetic and! Or dermato logical compositions intended for the treatment and prevention of skin conditions by topical application must be pleasant to use and present 'of good physical properties, especially consistency and smoothness, while
garantissant une efficacité satisfaisante. guaranteeing satisfactory efficiency.
Il est cependant difficile de concilier l'efficacité et l' aspect pratique d'application d'une composition destinée à la prévention et/ou la correction des affections dermato- logiques considérées. Dans l'état de la technique, on connaît notamment de l'enseignement du document FR-A- 2.7 61.607, une composition dermatologique pour le traitement des symptômes du vieillissement de la peau. Cette composition comporte au moins o un dérivé de silanol méthylé et au moins un dérivé d'une protéine végétale hydrolysce. Dans un autre mode de réalisation, cette composition comporte de plus un dérivé de vitamine C. Le silanol fait partie de la famille des dérivés organiques du silicium. Il est connu pour des utilisations dans les domaines dermatologique et cosmétique pour une application topique en vue de lutter contre le vieillissement However, it is difficult to reconcile the effectiveness and practicality of applying a composition intended for the prevention and / or correction of the dermatological conditions considered. In the state of the art, the teaching of document FR-A-2.7 61.607 discloses in particular a dermatological composition for the treatment of the symptoms of aging of the skin. This composition comprises at least o a derivative of methylated silanol and at least one derivative of a hydrolysed vegetable protein. In another embodiment, this composition also comprises a vitamin C derivative. Silanol is part of the family of organic silicon derivatives. It is known for uses in the dermatological and cosmetic fields for a topical application in order to fight against aging.
de la peau. Il a un effet connu de stimulation de la recons- skin. It has a known effect of stimulating recognition
truction de la barrière dermo-épidermique. Il stimule notamment la synChèse de collagène et d'élastine dans les truction of the dermo-epidermal barrier. In particular, it stimulates the synthesis of collagen and elastin in
cellules du derme.dermis cells.
Diverses compositions cosmétiques proposent d'utiliser des silanols ou des dérivés de silanols, par exemple en combinaison avec les acides mannuronique ou hyaluronique comme dans le brevet FR-A-2.611.496, ou avec un polysaccharide comme dans le brevet FR-A-2.667.240, ou sous forme de produit de condensation avec un acide aminé tel que la sérine, come dans le brevet EP-A-295.983. Selon le brevet FR-A-2. 761.607 précité, la combinaison proposée de méthyl-silanol et de protéine végétale hydrolysée est cocr.ue pour empêcher la formation de liaisons croisoes entre les protéines du tissu conjonctif de la peau, nota=ment entre les proté-nes de collagène. Ces liaisons croiséss se traduisent à lon terme par un raidissement du tissu et une perte d'élasticité de la peau. Dans la variante o la composition comporte de la vitamine C, celle-ci stimule la synChèse de néccollagène, et maintient un degré de glycosylation du collagène synthétisé Various cosmetic compositions propose the use of silanols or silanol derivatives, for example in combination with mannuronic or hyaluronic acids as in patent FR-A-2,611,496, or with a polysaccharide as in patent FR-A-2,667 .240, or in the form of a condensation product with an amino acid such as serine, as in patent EP-A-295,983. According to patent FR-A-2. 761.607 cited above, the proposed combination of methyl silanol and hydrolyzed vegetable protein is co-ordinated to prevent the formation of cross links between the proteins of the connective tissue of the skin, in particular between the collagen proteins. These cross-links result in the long term in a stiffening of the tissue and a loss of elasticity of the skin. In the variant where the composition comprises vitamin C, this stimulates the synechesis of neccollagen, and maintains a degree of glycosylation of the collagen synthesized
pour le protéger de la formation de ces liaisons croisées. to protect it from the formation of these cross links.
Elle inhibe ainsi la production de radicaux libres. It thus inhibits the production of free radicals.
Les compositions de l'état de la technique posent un problème car l'activité du silanol incorporé dans ces compositions est faible. En effet, les effets observés sont plus liés à la présence d'un apport de fibres qu'à une réelle The compositions of the prior art pose a problem because the activity of the silanol incorporated in these compositions is low. Indeed, the effects observed are more linked to the presence of an intake of fibers than to a real
stimulation des cellules liées au silanol. stimulation of cells linked to silanol.
Or, la demanderesse a découvert que la présence d'alpha hydroxy acides, ou de sels ou esters d' alpha hydroxy acides, dans les compositions cosmétiques procure une augmentation et une stimulation des effets procurés par le silanol, ou les Now, the Applicant has discovered that the presence of alpha hydroxy acids, or of alpha hydroxy acid salts or esters, in cosmetic compositions provides an increase and a stimulation of the effects provided by silanol, or the
dérivés du silanol.silanol derivatives.
L' invention a donc pour objet une composition pour la protection de la peau contenant au moins un alpha-hydroxy acide ou un de ses sels ou esters, en combinaison avec au The subject of the invention is therefore a composition for protecting the skin containing at least one alpha-hydroxy acid or one of its salts or esters, in combination with at least
moins un silanol.minus one silanol.
Plus particulièrement, la présente invention a pour objet une composition cosmétique, administrable par voie topique, présentant d'excellentes qualités d'utilisation et permettant de renforcer la protection de la peau contre les agressions extérieures et de favoriser le processus de réparation de More particularly, the present invention relates to a cosmetic composition, administrable by topical route, having excellent qualities of use and making it possible to strengthen the protection of the skin against external aggressions and to promote the repair process of
diverses affections cutances.various skin conditions.
L' invention a également pour objet une méthode de traitement cosmétique de la peau destinse à la prévention des symptômes liés au vieillissement de la peau, par application locale d'une composition à base de silanols et d'alpha-hydroxy acides sur peau et en particulier sur la zone de la peau la A subject of the invention is also a method of cosmetic treatment of the skin intended for the prevention of symptoms linked to aging of the skin, by local application of a composition based on silanols and alpha-hydroxy acids on the skin and in particular on the skin area the
plus exposée.more exposed.
Notamment, le silanol augmente le nombre de fibroblastes présents dans les couches du derme et de l'épiderme, en augmentant parallèlement la synthèse de collagène par ces In particular, silanol increases the number of fibroblasts present in the layers of the dermis and of the epidermis, by simultaneously increasing the synthesis of collagen by these
fibroblastes. Le derme est alors plus dense et p us résistant. fibroblasts. The dermis is then denser and more resistant.
Le silanol utilisé dans les compositions de l' invention est de s The silanol used in the compositions of the invention is of s
4 28244754 2824475
préférence un alkyl-silanol, et plus particulièrement un méthyl-silanol. De préférence, l'alpha-hydroxy acide est choisi parmi l'acide citrique, l'acide lactique, l'acide mandélique et l'acide glycolique, ou leurs sels ou esters, isolément ou en combinaison. Dans un mode de réalisation préféré, la composition comprend une proportion d'alpha-hydroxy acide et de dérivés d'alpha-hydroxy acides comprise entre 5% et 30% en poids par rapport au poids total de la composition. Dans un mode de réalisation particulier, l'alpha-hydroxy acide est présent sous forme d'un de ses sels ou esters. Ces sels et esters peuvent être utilisés isolément ou en mélange entre eux ou avec des alpha-hydroxy acides. Dans ce cas, de préférence le sel d'alpha-hydroxy acide représente entre 3 et 15 % en poids de la composition, et plus préférentiellement entre 5 et 10 %, et l' ester d'alpha-hydroxy acide représente entre 3 et 15 % en poids de la composition, et plus préférentiellement entre 5 et %. Les alpha-hydroxy acides tels que l'acide lactique, l'acide glycolique, l'acide mandélique ou l'acide citrique, facilitent l' exfoliation des cellules à la surface de l'égiderme. Dans les exemples décrits ci-après l'alpha-hydroxy acide choisi est l'acide citrique. Cet alpha-hydroxy acide améliore très sensiblement les mécanismes de desquamation, d'oxygénation et d'hydratation des cellules. De plus, il preferably an alkyl silanol, and more particularly a methyl silanol. Preferably, the alpha-hydroxy acid is chosen from citric acid, lactic acid, mandelic acid and glycolic acid, or their salts or esters, alone or in combination. In a preferred embodiment, the composition comprises a proportion of alpha-hydroxy acid and of alpha-hydroxy acid derivatives of between 5% and 30% by weight relative to the total weight of the composition. In a particular embodiment, the alpha-hydroxy acid is present in the form of one of its salts or esters. These salts and esters can be used individually or as a mixture with one another or with alpha-hydroxy acids. In this case, preferably the alpha hydroxy acid salt represents between 3 and 15% by weight of the composition, and more preferably between 5 and 10%, and the alpha hydroxy acid ester represents between 3 and 15 % by weight of the composition, and more preferably between 5 and%. Alpha-hydroxy acids such as lactic acid, glycolic acid, mandelic acid or citric acid facilitate the exfoliation of cells on the surface of the epidermis. In the examples described below, the alpha-hydroxy acid chosen is citric acid. This alpha-hydroxy acid very significantly improves the scaling, oxygenation and hydration mechanisms of cells. Moreover, he
stimule la synthèse des glycoaminoglycanes. stimulates the synthesis of glycoaminoglycans.
Pour optimiser la tolérance vis-à-vis de la présence d'alpha-hydroxy acide dans la composition, selon un mode de To optimize the tolerance vis-à-vis the presence of alpha-hydroxy acid in the composition, according to a method of
réalisation perfectionné, la composition comporte du galac-o- perfected realization, the composition includes galac-o-
arabinan (Laracare A2002) et ou un polyal prépolymère. Ils ont un pouvoir filmogène qui permet notamment de réquler les pertes en eau, tout en donnant un aspect doux et satiné à la composition. Outre l'alpha-hydroxy acide, une composition selon ce mode de réalisation préféré comprend une proportion de silanol méthylé, ou d'un dérivé du silanol méthylé, comprise entre 1 % et 20 % en poids par rapport au poids total de la composition, et plus préférentiellement entre 3 et 7 %, par exemple 5 % environ. Plusieurs composés peuvent être utilisés à titre de dérivés de silanol, et par exemple des mono-alkyl silane triols et des dialkyl silane diols o le groupe alkyle peut 0 comporter une chaîne linéaire ou ramifice de 1 à 12 atomes de carbone, et constituer par exemple un groupe méthyle, éthyle, propyle, isopropyle ou butyle. Parmi les dérivés de silanols les plus couramment utilisés, et plus particulièrement de méthyl silanol, on peut mentionner entre autres le mannuronate de sodium de méthylsilanol (Algisiumê), le mannuronate de méthylsilanol (Algisium C), le hyaluronate de diméthylsilanol (D.S.H.C@), le hyaluronate de sodium de diméthylsilanol (D.S.Hô), le lactate de sodium de méthylsilanol (Lasiliumê), l'ascorbyl-méthylsilanol (Ascorbosilane concentré C), le glycyrrhizinate de méthylsilanol (Glysinolô), l'hydroxyproline arabinan (Laracare A2002) and or a prepolymer polyal. They have a film-forming power which makes it possible in particular to adjust the water losses, while giving a soft and satin appearance to the composition. In addition to alpha-hydroxy acid, a composition according to this preferred embodiment comprises a proportion of methylated silanol, or of a derivative of methylated silanol, of between 1% and 20% by weight relative to the total weight of the composition, and more preferably between 3 and 7%, for example around 5%. Several compounds can be used as silanol derivatives, and for example mono-alkyl silane triols and dialkyl silane diols o the alkyl group can 0 comprise a straight chain or branching from 1 to 12 carbon atoms, and constitute for example a methyl, ethyl, propyl, isopropyl or butyl group. Among the most commonly used silanol derivatives, and more particularly methyl silanol, there may be mentioned, inter alia, methylsilanol sodium mannuronate (Algisiumê), methylsilanol mannuronate (Algisium C), dimethylsilanol hyaluronate (DSHC @), dimethylsilanol sodium hyaluronate (DSHô), methylsilanol sodium lactate (Lasiliumê), ascorbyl-methylsilanol (concentrated Ascorbosilane C), methylsilanol glycyrrhizinate (Glysinolô), hydroxyproline
méthyleilanol (Hydroxyprolisilane), l'aspartate d'hydroxypro- methylilanol (Hydroxyprolisilane), hydroxypro- aspartate
line méthylsilanol (Hydroxyprolisilane Cô, l'acétylméthionate line methylsilanol (Hydroxyprolisilane Cô, acetylmethionate
de méthylsilanol (Methiosilane), l'élastinate d'acétylméthio- methylsilanol (Methiosilane), acetylmethio- elastinate
nylméthylsilanol (Methiosilane Cô), le cocoste de méthyl 2s silanol-PEG-7glycéryle (Monosiliolô), et l'acétyltyrosinate de méthylsilanol (Tyrosilane). Tous ces dérivés de silanol sont disponibles dans le commerce, et sont produits notamment nylmethylsilanol (Methiosilane Cô), the cocost of methyl 2s silanol-PEG-7glyceryl (Monosiliolô), and the acetyltyrosinate of methylsilanol (Tyrosilane). All of these silanol derivatives are commercially available, and are produced in particular
par la société Exsymol.by the company Exsymol.
Parmi les dérivés de silanol méthylé prétérés dans le contexte de la présente invention, on peut mentionner plus particulièrement le mannuronate de méthylsilanol, l'ascorbyl méthylsilanol, l'hydroxyproline méthylsilanol, et l'aspartate d'hydroxyproline méthylailanol. De préférence on utilise dans les compositions de l' invention l'aspartate d'hydroxyproline Among the methyl silanol derivatives claimed in the context of the present invention, there may be mentioned more particularly methylsilanol mannuronate, ascorbyl methylsilanol, hydroxyproline methylsilanol, and hydroxyproline aspartate methylailanol. Preferably, in the compositions of the invention, hydroxyproline aspartate is used.
méthylsilanol (Hydroxyprolisilane C, Exsymol). methylsilanol (Hydroxyprolisilane C, Exsymol).
Pour améliorer l' action de la composition une fois absorbée par les couches supérieures de la peau, la composition comprend de la vitamine C, de préférence sous forme de sel ou d' ester dérivés de l'acide ascorbique. La s vitamine C, en combinaison avec les alpha-hydroxy acides, présente l'avantage d'exercer une action anti-radicalaire et une exfoliation douce accompagnce d'une kératoréqulation, To improve the action of the composition once absorbed by the upper layers of the skin, the composition comprises vitamin C, preferably in the form of a salt or an ester derived from ascorbic acid. Vitamin C, in combination with alpha-hydroxy acids, has the advantage of exerting an anti-radical action and gentle exfoliation accompanied by keratorequlation,
tandis que, associée aux silanols, elle favorise la restau- while, associated with silanols, it promotes the restoration
ration de la janction dermo-épidermique et la synChèse des ration of the dermo-epidermal union and the synchesis of
glycosaminoglycanes.glycosaminoglycans.
Les concentrations en vitamine C ou en l'un de ses dérivés peuvent généralement varier de 0,1 à 5 % en poids, les concentrations préférées se situant habituellement entre O,S The concentrations of vitamin C or one of its derivatives can generally vary from 0.1 to 5% by weight, the preferred concentrations usually being between O, S
et 2 % en poids par rapport au poids total de la composition. and 2% by weight relative to the total weight of the composition.
La vitamine C, ou l'un de ses dérivés (par exemple, le tétra-isopalmitate d'ascorbyle ou l'ascorbate de tétra hexyl décyle) compris dans la composition de l' invention, peut encore améliorer le procédé de traitement anti-vieillissement, car elle contrôle les troubles de la pigmentaion, et elle limite l'atrophie du derme et de l'épiderme en favorisant, elle aussi, la synChèse de collagène. De plus, la vitamine C Vitamin C, or one of its derivatives (for example, ascorbyl tetra-isopalmitate or tetra hexyl decyl ascorbate) included in the composition of the invention, can further improve the anti-aging treatment process , because it controls the disorders of the pigmentaion, and it limits the atrophy of the dermis and the epidermis while supporting, it, too, the synChèse of collagen. In addition, vitamin C
apporte à la peau un système antiradicalaire. provides the skin with an anti-free radical system.
Des dérivés stables de la vitamine C peuvent être choisis parmi les sels ou les esters d'ascorbyle ainsi cue les formes 2s encapsulées de la vitamine C: ascorbate de magnésium (Vitacedone@, UCIB), phosphate d'ascorbyle et de magnésium (Nikkal VC-PMG3, Jan Dekker), palmitate d'ascorbyle, pectinate d'ascorbylméthylsilanol (AscorUilane C, Exsymol, polypeptide d'acide ascorbique (Vitazyme C, Brocks). O- peut aussi 3c utiliser des microsphères dont la paroi est de l- carraghénane encapsulant de la vitamine C (Lipotec$) ou des microsphères dont la paroi est de l'atélocollagène encapsu2an le phosphate d'ascorbyle et magnésium (Thallaspheres de la société Coletica). En plus de stimuler la production de collagène, une composition selon l' invention peut avantageusement contenir des agents dégigmentants. En effet, l'un des symptômes du vieillissement est l' apparition de tâches, généralement de couleur brunâtre, sur le dessus des mains ainsi que sur les avant bras, et le haut des épaules. Ces agents dépigmentants Stable derivatives of vitamin C can be chosen from the salts or ascorbyl esters thus cue the encapsulated 2s forms of vitamin C: magnesium ascorbate (Vitacedone @, UCIB), ascorbyl and magnesium phosphate (Nikkal VC -PMG3, Jan Dekker), ascorbyl palmitate, ascorbylmethylsilanol pectinate (AscorUilane C, Exsymol, ascorbic acid polypeptide (Vitazyme C, Brocks). O- can also use microspheres whose walls are l-carrageenan encapsulating vitamin C (Lipotec $) or microspheres whose wall is atelocollagen encapsu2an ascorbyl phosphate and magnesium (Thallaspheres from the company Coletica) In addition to stimulating the production of collagen, a composition according to The invention may advantageously contain degigmenting agents, in fact one of the symptoms of aging is the appearance of spots, generally of brownish color, on the top of the hands as well as on the forearms, and the ha ut of the shoulders. These depigmenting agents
et éclaircissants permettent de masquer ces tâches. and lightening masks these tasks.
La composition selon l' invention comprend par exemple de la glabridine. La glabridine est connue pour inLiber la production de mélanine par les cellules du derme, bloquant une enzyme, principalement la tyrosinase, mise en _uvre dans la synthèse de la mélanine. Outre la glabridine, les agents dépigmentants peuvent être choisis parmi l'extrait soluble dans l'huile de licorice, l'extrait de réglisse, l'extrait de licochalone. D'autres dépigmentants peuvent aussi être utilisés dans la composition suivant l' invention, et par exemple un dérivé The composition according to the invention comprises for example glabridin. Glabridin is known to inhibit the production of melanin by the cells of the dermis, blocking an enzyme, mainly tyrosinase, used in the synthesis of melanin. In addition to glabridin, the depigmenting agents can be chosen from the extract soluble in licorice oil, licorice extract, licochalone extract. Other depigmentants can also be used in the composition according to the invention, for example a derivative
d' acide ascorUique tel que le tétraisopalmitate d' ascorbyle. ascorUic acid such as ascorbyl tetraisopalmitate.
Dans une telle composition, les alpha-hydroxy acides In such a composition, the alpha hydroxy acids
renforcent l' action de ces agents dégigmentants. reinforce the action of these degigmenting agents.
La composition suivant la présente invention peut en outre contenir divers adjuvants et excipients couramment utilisés dans les techniques des compositions cosmétiques et dermatologiques. Elle peut par exemple contenir des conservateurs, des épaississants, des gélifiants hydrophiles ou lipophiles, des agents émulsionnants, des agents humectants, des antioxydants, des agents hydratants, des tensioactifs, des parfums, et divers additifs destinés à The composition according to the present invention may also contain various adjuvants and excipients commonly used in the techniques of cosmetic and dermatological compositions. It can for example contain preservatives, thickeners, hydrophilic or lipophilic gelling agents, emulsifying agents, humectants, antioxidants, hydrating agents, surfactants, perfumes, and various additives intended for
améliorer les propriétés physiques de la composition. improve the physical properties of the composition.
3c Les gélifiants ou épaississants peuvent par exemple être - choisis parmi les copolymères d'acrylate, par exemple le méthacrylate de polyméthyle, ou des gomes naturelles, par exemple une gemme de xanthane. Un composant tel que la perfluerodecaline peut être avantageusement incorpoé pour 3c The gelling agents or thickeners may for example be - chosen from acrylate copolymers, for example polymethyl methacrylate, or natural gomes, for example a xanthan gem. A component such as perfluerodecaline can be advantageously incorporated for
améliorer l'onctuosité d'une telle composition. improve the smoothness of such a composition.
L' agent hydratant ou humectant peut être choisi parmi un polyol, le sorbitol, le maltitol, le pentaéryChritol, la glycérine, le glycol, le propylène glycol, le polyéthylène glycol, le phénoxyethanol, les polyacrylates et polymétha crylates de glycéryle, le glycérol ou des dérivés du glycérol. D'une manière générale, tout agent hydratant convenant aux compositions cosmétiques ou dermatologiques peut être utilisé The moisturizing or moisturizing agent can be chosen from a polyol, sorbitol, maltitol, pentaerythritol, glycerin, glycol, propylene glycol, polyethylene glycol, phenoxyethanol, polyacrylates and polymetha crylates of glyceryl, glycerol or glycerol derivatives. In general, any moisturizing agent suitable for cosmetic or dermatological compositions can be used
dans la présente invention. L' agent humectant est avanta- in the present invention. The humectant is preferably
geusement introduit dans la phase aqueuse lors de la préparation de l'émulaion. La teneur en agent humectant est généralement comprise entre 0,1 et 5 en poids par rapport au carefully introduced into the aqueous phase during the preparation of the emulaion. The content of humectant is generally between 0.1 and 5 by weight relative to the
poids total de l'émulsion.total weight of the emulsion.
Les conservateurs usuels de la technique des compositions cosmétiques ou dermatologiques peuvent être utilisés dans l' invention, et par exemple l'acide benzaique et des parahydroxybenzoates de méthyle et/ou de propyle, isolément ou The usual preservatives of the technique of cosmetic or dermatological compositions can be used in the invention, and for example benzaic acid and methyl and / or propyl parahydroxybenzoates, alone or
en combinaison, ou encore la chlorphénésine. in combination, or chlorphenesin.
Des agents de protection contre les rayons ultra-violets peuvent également être utilisés. Ces agents de protection peuvent être par exemple des filtres solaires tels que la benzophénone ou un dérivé de benzophénone, ou un cinnamate et Protective agents against ultraviolet rays can also be used. These protective agents can for example be sunscreens such as benzophenone or a benzophenone derivative, or a cinnamate and
plus particulièrement le méthoxycinnamate d'éthylhexyle. more particularly ethylhexyl methoxycinnamate.
On peut aussi utiliser des pigments formant écran anti- You can also use pigments forming an anti-
ultraviolet, qui peuvent par exemple être choisis parmi le ultraviolet, which can for example be chosen from the
dioxyde de titane, l'oxyde de zinc ou encore d'aluminium. titanium dioxide, zinc oxide or aluminum oxide.
Les compositions peuvent se présenter sous forme de crèmes, émulsions huile-dans-eau ou émulsions eau-dans-huile, laits, gels, lotioris, masques, sticks ou pommades, et peuver.t être utilisées en particulier pour la protection de la peau contre les diverses agressions résultant généralement de l'environnement des utilisateurs, par exemple les agressions climatiques (vent, froid, pluie, etc.), chimiques (détergents) The compositions can be in the form of creams, oil-in-water emulsions or water-in-oil emulsions, milks, gels, lotioris, masks, sticks or ointments, and can be used in particular for protecting the skin. against various aggressions generally resulting from the environment of the users, for example climatic aggressions (wind, cold, rain, etc.), chemical aggressions (detergents)
ou la pollution.or pollution.
Un mode de réalisation préféré de l' invention se présente sous forme de crème pour les mains, cette crème pouvant A preferred embodiment of the invention is in the form of a hand cream, this cream being able to
9 28244759 2824475
éventuellement être également appliquée sur les avant.bras qui possibly also be applied to the forearms which
présentent un même type de peau que le dessus des mains. have the same skin type as the top of the hands.
La composition de l' invention se révèle particulièrement utile et efficace pour assurer les soins quctidiens de la peau, en particulier chez les sujets à peau fragile ou exposés à des risques d'agression de l'environnement ou d' affections diverses. Les caractéristiques et avantages de la présente The composition of the invention proves to be particularly useful and effective for ensuring daily care of the skin, in particular in subjects with fragile skin or exposed to risks of environmental aggression or various affections. The features and advantages of this
invention apparaîtront plus en détail dans la description qui invention will appear in more detail in the description which
o suit, relative à des formes préférentielles de réalisation. o follows, relating to preferred embodiments.
Dans ces exemples, les parties et pourcentages sont exprimés In these examples, the parts and percentages are expressed
en poids, sauf indication contraire. by weight, unless otherwise indicated.
Exemple 1Example 1
On prépare une crème pour les mains, en utilisant les techniques usuelles de l'industrie des produits cosmétiques et dermatologiques. La composition pondérale de la crème est indiquée ci après. Eauq.s.p. 100,00 23 Acide citrique7,50 Citrate de sadium7,50 Triglycérides caprique et caprylique5,00 Méthoxyainnamate d'éthylhexyle5,00 Benzophénone-35,00 Aspartate d'hydroxyproline méthylsilanol5,00 Méthacrylate de polyméthyle2, 00 Glycérine.3,00 Isohexadécane3,00 Tétra-isopalmitate d'ascorbyle1,00 PEG 30 dipolyhydroxystéarate1,00 SulLate de magnéaium0,80 Perfluorodécaline0,75 Phénoxyéthanol / parahydroxyLenzoate d'alkyle 0,60 t' 1L' Glabridine*. 0,50 Parfum0 40 Chlorphénésine0,20 * Solution aqueuse de GlycyrrRiza glabra (Licorice) A hand cream is prepared, using the usual techniques of the cosmetic and dermatological industry. The weight composition of the cream is indicated below. Eauq.s.p. 100.00 23 Citric acid7.50 Sadium citrate7.50 Capric and caprylic triglycerides 5.00 Ethylhexyl methoxyainnamate 5.00 Benzophenone-35.00 Hydroxyproline methylsilanol aspartate 5.00 Polymethyl methacrylate 2.00 Glycerin 3.00 Isohexadecane3.00 Ascorbyl tetra-isopalmitate1.00 PEG 30 dipolyhydroxystearate1.00 Magnesium sulLate0.80 Perfluorodecaline0.75 Phenoxyethanol / parahydroxyLenzoate 0.60 t '1L' Glabridine *. 0.50 Perfume0 40 Chlorphenesine0.20 * Aqueous solution of GlycyrrRiza glabra (Licorice)
Exemple 2Example 2
On prépare dans cet exemple une crème ayant la In this example, a cream is prepared having the
composition pondérale indiquce ci-après. weight composition indicated below.
Eau q.s.p. 100,00 Acide citrique 7,50 Citrate de sodium 7,S0 Citrate de tri,C12-13,alkyle 10,00 Triglycérides caprique et caprylique 6,00 Glucoside d'alkyl (C12-20) / alcool (C14-22) 5,00 :5 Ascorbate de tétrahexyl-décyle 1,00 Butylène glycol 0,45 Aspartate d'hydroxyproline méthylsilanol 5,00 Galacto arabinane 2,00 Succinate d'ammonium 5,00 Ammonium poly-(acryldiméthyltauramide-CO vinylformamide) 1,00 Propylène glycol / diazolidinylurée / para hydroxybenzoate d'alkyle 1,00 Gomme de xanthane 0,50 2 Glabridine 0,05 Une crème ayant la composition ci-dessus peut être appliquée sur les mains et les bras en couche mince réqulière Water q.s.p. 100.00 Citric acid 7.50 Sodium citrate 7, S0 Sorting citrate, C12-13, alkyl 10.00 Capric and caprylic triglycerides 6.00 Alkyl glucoside (C12-20) / alcohol (C14-22) 5 .00: 5 Tetrahexyl-decyl ascorbate 1.00 Butylene glycol 0.45 Hydroxyproline methylsilanol aspartate 5.00 Galacto arabinane 2.00 Ammonium succinate 5.00 Ammonium poly- (acryldimethyltauramide-CO vinylformamide) 1.00 Propylene glycol / diazolidinylurea / alkyl hydroxybenzoate 1.00 Xanthan gum 0.50 2 Glabridin 0.05 A cream having the above composition can be applied to the hands and arms in a regular thin layer
plusieurs fois par jour.several times a day.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0106271A FR2824475B1 (en) | 2001-05-11 | 2001-05-11 | COSMETIC COMPOSITION FOR SKIN PROTECTION, COMPRISING ALPHA-HYDROXY ACID AND SILANOL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0106271A FR2824475B1 (en) | 2001-05-11 | 2001-05-11 | COSMETIC COMPOSITION FOR SKIN PROTECTION, COMPRISING ALPHA-HYDROXY ACID AND SILANOL |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2824475A1 true FR2824475A1 (en) | 2002-11-15 |
FR2824475B1 FR2824475B1 (en) | 2005-03-25 |
Family
ID=8863189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0106271A Expired - Fee Related FR2824475B1 (en) | 2001-05-11 | 2001-05-11 | COSMETIC COMPOSITION FOR SKIN PROTECTION, COMPRISING ALPHA-HYDROXY ACID AND SILANOL |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2824475B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011026039A1 (en) * | 2009-08-28 | 2011-03-03 | Mary Kay Inc. | Skin care formulations |
US11298391B1 (en) * | 2017-04-27 | 2022-04-12 | Lorenol Laboratories, Inc. | Topical skin health improvement compositions and administrations thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2611496A1 (en) * | 1987-03-04 | 1988-09-09 | Gueyne Jean | COSMETIC ORGANIC SILICIES |
EP0380335A2 (en) * | 1989-01-27 | 1990-08-01 | Lancaster Societe Anonyme Monegasque | Sun tan accelerator compositions |
FR2667240A1 (en) * | 1990-09-27 | 1992-04-03 | Innovation Scient Dermatol | Active complex for dermocosmetic treatment products |
JPH0812518A (en) * | 1994-06-27 | 1996-01-16 | Maruzen Pharmaceut Co Ltd | Skin cosmetic |
WO1997026892A1 (en) * | 1996-01-26 | 1997-07-31 | Laboratoires Carilene | Combinations of peroxide lipids and organosilicon compounds, cosmetic and dermatological compositions containing same, and uses thereof, in particular for treating alopecia |
FR2761607A1 (en) * | 1997-04-04 | 1998-10-09 | Boots Co Plc | DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF SKIN AGING SYMPTOMS |
-
2001
- 2001-05-11 FR FR0106271A patent/FR2824475B1/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2611496A1 (en) * | 1987-03-04 | 1988-09-09 | Gueyne Jean | COSMETIC ORGANIC SILICIES |
EP0380335A2 (en) * | 1989-01-27 | 1990-08-01 | Lancaster Societe Anonyme Monegasque | Sun tan accelerator compositions |
FR2667240A1 (en) * | 1990-09-27 | 1992-04-03 | Innovation Scient Dermatol | Active complex for dermocosmetic treatment products |
JPH0812518A (en) * | 1994-06-27 | 1996-01-16 | Maruzen Pharmaceut Co Ltd | Skin cosmetic |
WO1997026892A1 (en) * | 1996-01-26 | 1997-07-31 | Laboratoires Carilene | Combinations of peroxide lipids and organosilicon compounds, cosmetic and dermatological compositions containing same, and uses thereof, in particular for treating alopecia |
FR2761607A1 (en) * | 1997-04-04 | 1998-10-09 | Boots Co Plc | DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF SKIN AGING SYMPTOMS |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 199612, Derwent World Patents Index; AN 1996-112588, XP002192238 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011026039A1 (en) * | 2009-08-28 | 2011-03-03 | Mary Kay Inc. | Skin care formulations |
CN102711721A (en) * | 2009-08-28 | 2012-10-03 | 玫琳凯公司 | Skin care formulations |
CN102711721B (en) * | 2009-08-28 | 2013-09-25 | 玫琳凯公司 | Skin care formulations |
EA023290B1 (en) * | 2009-08-28 | 2016-05-31 | Мэри Кей Инк. | Method of treating skin and topical composition for rejuvenating, replenishing and firming skin during sleep |
US9833642B2 (en) | 2009-08-28 | 2017-12-05 | Mary Kay Inc. | Skin care formulations |
US10434340B2 (en) | 2009-08-28 | 2019-10-08 | Mary Kay Inc. | Skin care formulations |
US11123578B2 (en) | 2009-08-28 | 2021-09-21 | Mary Kay Inc. | Skin care formulations |
US11596813B2 (en) | 2009-08-28 | 2023-03-07 | Mary Kay Inc. | Skin care formulations |
US11679284B2 (en) | 2009-08-28 | 2023-06-20 | Mary Kay Inc. | Skin care formulations |
US12097393B2 (en) | 2009-08-28 | 2024-09-24 | Mary Kay Inc. | Skin care formulations |
US11298391B1 (en) * | 2017-04-27 | 2022-04-12 | Lorenol Laboratories, Inc. | Topical skin health improvement compositions and administrations thereof |
Also Published As
Publication number | Publication date |
---|---|
FR2824475B1 (en) | 2005-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4256389B2 (en) | Composition comprising a mixture of tetrapeptide and tripeptide | |
EP0414608B1 (en) | Cosmetic compositions containing chitosane and glucosamine | |
US5441740A (en) | Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain | |
EP1021161B1 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
WO2008139122A2 (en) | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same | |
CH661205A5 (en) | COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR SKIN CARE. | |
FR2885522A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING TEPRENONE | |
FR2746316A1 (en) | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS | |
FR2755368A1 (en) | RINCABLE COMPOSITION FOR SKIN CARE | |
EP1572148B1 (en) | Cosmetic composition comprising a siegesbeckia extract and a lipopeptide | |
FR2736829A1 (en) | COMPOSITION FOR PREVENTING SKIN TASKS AND / OR SKIN AGING, USES THEREOF | |
FR2742987A1 (en) | USE IN THE FIELD OF COSMETICS AND PHARMACY, IN PARTICULAR DERMATOLOGY, OF AN EXTRACT FROM ERIOBOTRYA JAPONICA FOR STIMULATING THE SYNTHESIS OF GLYCOSAMINOGLYCANS | |
FR2896154A1 (en) | Cosmetic/dermatological composition, useful for treatment of skin against external aggressions, comprises chestnut leaves extract, chestnut milk, chestnut sugar and an essential oil | |
EP2148727A2 (en) | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, methods for the preparation thereof, and uses thereof | |
EP1530480B1 (en) | Cosmetic composition comprising monosaccharides or polysaccharides, uses and treatment methods | |
CA2470102C (en) | Novel combination containing a poloxamer and chondroitin sulphuric acid and/or a glycoprotein and use thereof | |
FR2824475A1 (en) | New topical composition containing silanol and alpha hydroxy acids to enhance its antiaging effects, is useful for preventing symptoms of skin aging | |
EP2868313B1 (en) | Combination of vitamin C and hyaluronic acid for the treatment of skin ageing effects | |
JP2006219432A (en) | Composition having rough skin-preventing activity, cosmetic and beverage | |
CN112545970B (en) | Pearl cream for beauty and skin care and preparation method thereof | |
CN115737456A (en) | Skin cleaning scrub cream and preparation method thereof | |
FR2687312A1 (en) | Compositions for application to the skin intended for the treatment and prevention of wrinkles and shadows under the eyes. | |
JP2006219431A (en) | Composition having rough skin-preventing activity, cosmetic and beverage | |
FR2930727A1 (en) | COMPOSITION FOR THE TREATMENT OF SEBORRHEIC STATES. | |
FR3128371A3 (en) | Cosmetic or dermatological composition comprising succinic acid for preventing, reducing or eliminating skin imperfections and treating skin disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20060131 |